← back to search

Zairong Gao

Ministry of Education of the People's Republic of China · CN
Area of research
Endocrinology, Diabetes and Metabolism · Radiology, Nuclear Medicine and Imaging
Research interest
Research focused on Apatinib and Thyroid cancer, with related work in Cancer, Anaplastic thyroid cancer, Sorafenib. Notable publications include 'Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid Cancer', 'Nanomedicine for renal cell carcinoma: imaging, treatment and beyond', and 'Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer'.
h-index
citations
114
works
5
NIH funding
primary concept
email

Recent publications

RhTSH in aiding dynamic assessment in patients with differentiated thyroid Cancer
European Journal of Nuclear Medicine and Molecular Imaging 2025cited by 1position: middledoi
Nanomedicine for renal cell carcinoma: imaging, treatment and beyond
Journal of Nanobiotechnology 2023cited by 24position: middledoi
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Clinical Cancer Research 2023cited by 21position: middledoi
Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy
Journal of Nanobiotechnology 2023cited by 15position: middledoi
Apatinib versus placebo in patients with locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: Post hoc analyses from the REALITY randomized clinical trial.
Journal of Clinical Oncology 2022cited by 1position: middledoi
Donafenib in Locally Advanced/Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (DIRECTION)
Research Square 2022cited by 0position: middledoi
Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid Cancer
JAMA Oncology 2021cited by 91position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Linfa Li · Tianjin University3 papers (2021–2025)Guang Chen · Anhui Medical University2 papers (2021–2022)Shaohua Li · Jilin Agricultural University2 papers (2021–2022)Zhiyong Li · Hubei University of Technology2 papers (2022–2025)Chenyang Wang · Fudan University2 papers (2023–2023)Jingjing Wang · Ministry of Education of the People's Republic of China2 papers (2023–2023)Jun Liang · Chongqing Medical University2 papers (2021–2022)Wenxin Chen · Fujian Medical University2 papers (2021–2022)Shanghua Jing · Hebei Medical University2 papers (2021–2022)Ruolin Wu · Ministry of Education of the People's Republic of China2 papers (2023–2023)Yansong Lin · Sun Yat-sen University2 papers (2021–2025)Dawei Jiang · 82th Hospital of Pla2 papers (2023–2023)Weibing Miao · Xiamen University2 papers (2021–2022)Shukui Qin · Affiliated Hospital of Southwest Medical University2 papers (2021–2022)Jiandong Bao · Zhejiang University2 papers (2021–2022)Xiaotian Xia · Ministry of Education of the People's Republic of China2 papers (2023–2023)Chenghe Lin · Jilin University2 papers (2021–2022)Qing Zhang · Tongji University1 papers (2022–2022)Hong Zhang · Sun Yat-sen University1 papers (2021–2021)Yue Chen · Central South University1 papers (2025–2025)